POSC377 Twelve-Month Follow up of Ixekizumab in the Badbir Registry: Baseline Demographics, Drug Survival and Effectiveness in Biologic-Naïve Versus Biologic-Experienced Patients with Psoriasis
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.1202
https://www.valueinhealthjournal.com/article/S1098-3015(21)02997-1/fulltext
Title :
POSC377 Twelve-Month Follow up of Ixekizumab in the Badbir Registry: Baseline Demographics, Drug Survival and Effectiveness in Biologic-Naïve Versus Biologic-Experienced Patients with Psoriasis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02997-1&doi=10.1016/j.jval.2021.11.1202
First page :
Section Title :
Open access? :
No
Section Order :
10740